Lose Weight Without Injections:
The Wegovy Pill Has Been Approved
Wegovy Pill in Germany: Approved, but Not Yet Available in Pharmacies
The Wegovy pill containing the active ingredient semaglutide has been approved in the EU since July 15, 2026, making it the first oral GLP-1 receptor agonist approved for weight management. When it will become available in Germany, remains uncertain: regulatory approval does not mean immediate availability, as the product must first be launched on the market.
- EU Approval
- July 15, 2026
- Valid throughout the EU, including Germany.
- German Market Launch
- Third Quarter of 2026
- Manufacturer estimate. No confirmed date.
- Availability
- Prescription Only
- Prescription medication dispensed through pharmacies.
What can already be assessed is whether medication-assisted weight loss may be appropriate for you. This medical evaluation is always the first step, regardless of which medication is currently available.
Free and without obligation. Submitting an inquiry does not automatically result in a prescription.
Learn About Effects, Administration, and Dosage →Wegovy Pill: Market Launch, Effects, and What Daily Use Requires
Go directly to the section most relevant to you.
- Market Launch & Cost
- Who It Is Approved For
- Daily Administration
- Effects & Weight Loss
- Pill or Injection
- Frequently Asked Questions
Medical Notice: This article is intended for general informational purposes and does not replace individualized medical advice. Treatment with semaglutide may only begin after a medical assessment and a physician’s prescription. Study results are averages and cannot reliably predict an individual’s weight-loss outcome.
The Wegovy Pill in Nine Key Points
The oral form of Wegovy expands the available treatment options for obesity. It is a prescription medication and is not appropriate for everyone.
- 01
EU Approval Granted
The oral form of Wegovy was approved in the European Union on July 15, 2026.
- 02
Market Launch Expected in Q3
The manufacturer expects the product to launch in Germany in the third quarter of 2026. No specific date has been confirmed.
- 03
Fifth Regulatory Approval Worldwide
Before the EU, the United States, the United Kingdom, the United Arab Emirates, and Bahrain had already granted approval.
- 04
Adults Only
Approved for adults with a BMI of 30 kg/m² or higher, or a BMI of 27 kg/m² or higher with at least one weight-related comorbidity.
- 05
Once Daily on an Empty Stomach
Take after fasting for at least eight hours, followed by a waiting period of at least 30 minutes.
- 07
A Consistent Daily Routine Is Required
No injection pen and no injection, but a reliable daily routine and strict fasting conditions are required.
- 08
Not the Same as Rybelsus
Both contain semaglutide. Rybelsus has a different approved indication, dosage, and use.
- 09
A Medical Assessment Determines Eligibility
BMI, comorbidities, other medications, potential risks, and suitability for daily life must be assessed individually by a physician.
What Exactly Was Approved for the Wegovy Pill?
The approval covers a new dosage form, not a new active ingredient. The active ingredient semaglutide, already used in the Wegovy injection, is now also available as a once-daily tablet.
On May 21, 2026, the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended expanding the existing Wegovy authorization. The European Commission issued its formal decision on July 15, 2026.
This provides patients with an additional treatment option that does not require injections. However, a tablet is not automatically easier or better suited to every patient. The approved indication, daily dosing routine, possible side effects, other medications, and long-term support must all be considered together.
-
May 21, 2026
Positive Recommendation
The EMA’s CHMP recommends approval of the oral dosage form.
-
July 15, 2026
EU Approval
The European Commission grants approval for the Wegovy pill.
-
Q3 2026
Market Launch
The manufacturer expects the product to become available in Germany during the third quarter.
-
After Launch
Prescribing Becomes Possible
Dispensed through pharmacies only after a medical assessment and with a prescription.
For context: The Wegovy pill had already been approved in the United States, the United Kingdom, the United Arab Emirates, and Bahrain before receiving EU approval. The European decision is therefore the fifth regulatory approval worldwide. However, experience in these markets cannot be applied directly to the availability and supply situation in Germany.
Who Is the Wegovy Pill Approved For?
The Wegovy pill is intended exclusively for adults. It is used in combination with a reduced-calorie diet and increased physical activity.
-
30+
BMI of 30 kg/m² or Higher
A BMI at or above this level is medically classified as obesity. A physician must still determine whether treatment is appropriate for the individual patient.
-
27+
BMI of 27 or Higher With a Comorbidity
For a BMI from 27 to under 30 kg/m², at least one weight-related comorbidity must also be present. Examples include prediabetes, type 2 diabetes, high blood pressure, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.
BMI Is Only the Starting Point. Meeting the formal criteria does not automatically mean that treatment is medically appropriate or safe. The physician’s benefit-risk assessment considers factors including weight history, previous weight-loss attempts, blood pressure, blood glucose, lipid metabolism, current medications, possible contraindications, plans for pregnancy, pregnancy, and breastfeeding. You can calculate your current value in advance with our BMI calculator.
Although the injectable form of Wegovy may be used in adolescents age 12 and older under certain conditions, the published EU indication states that the oral dosage form is intended exclusively for adults.
What Daily Administration Means in Practice
Not needing an injection may sound more convenient. However, the Wegovy pill has four specific administration requirements that must be followed every day:
- Fast for at least eight hours before taking the tablet
- Take it on an empty stomach with a small amount of water
- Wait at least 30 minutes afterward
- Do not eat, drink, or take any other oral medication during this period
Food, beverages, and medications taken at the same time can affect the absorption of oral semaglutide. These instructions are therefore part of the treatment regimen, not optional recommendations.
Daily Use May Be Easier to Integrate If …
- you can maintain a consistent daily routine after an extended fasting period,
- you can wait at least 30 minutes before breakfast or beverages,
- you can take other medications at a different time,
- you can reliably take the medication every day,
- injections are a significant barrier for you.
Discuss With Your Physician Before Starting Treatment If …
- shift work or changing daily schedules make a consistent routine difficult,
- you take several oral medications at fixed times,
- you need food or beverages immediately in the morning,
- you often forget daily medications,
- you already have significant gastrointestinal symptoms.
This Does Not Automatically Mean That the Wegovy Pill Is Unsuitable. However, these points should be discussed with a physician before treatment begins and considered when selecting the dosage form. You can find an overview of oral treatment options on our page about weight loss with tablets.
Dosage and Dose Escalation in Detail
The EU approval covers four strengths, ranging from 1.5 mg to the 25 mg treatment dose. Our medication page provides complete information about gradual dose escalation, the applicable intervals, drug interactions, and contraindications.
View the Wegovy Pill →A New Option Without Injections, but Not Without a Medical Assessment.
Whether the Wegovy pill, a weight-loss injection or an approach without medication is right for you depends on your medical situation, not the medication’s brand name.
Care is available throughout Germany by video consultation or at one of our locations.
How Effective Is the Wegovy Pill?
A key basis for approval was the randomized, double-blind, placebo-controlled phase 3b trial OASIS 4 involving 307 adults without diabetes. The trial lasted 71 weeks, and the primary efficacy endpoints were assessed at week 64.
- 205 participants received 25 mg of oral semaglutide once daily.
- 102 participants received a placebo once daily.
- 76.3% of the semaglutide group achieved at least 5% weight loss.
- 30.5% of the placebo group achieved at least 5% weight loss.
Why Are Both 13.6% and 16.6% Reported?
The Wegovy pill is often described as producing “around 17% weight loss.” This figure comes from one specific statistical analysis and is not the only result reported in OASIS 4. Both analyses are based on the same trial, but they account for treatment discontinuations and additional therapies differently.
Analysis Including Treatment Discontinuations
This analysis includes outcomes regardless of whether treatment was discontinued early or additional therapy was started. Placebo: −2.2%. It reflects events that may occur during real-world treatment.
Assuming Continuous Treatment
This statistical scenario assumes that treatment was continued as intended and that no additional therapy was started. Placebo: −2.7%. This result is the basis for the rounded figure of “around 17%.”
Important: All figures are average results from a controlled clinical trial. They do not reliably predict an individual patient’s weight-loss outcome and do not promise a specific amount of weight loss. Individual results depend on factors including starting weight, medical status, nutrition, physical activity, adherence, tolerability, and long-term support.
OASIS 4 was funded by Novo Nordisk. In addition to independent researchers, company employees were involved in the publication. This should be considered transparently when interpreting the results.